Got 90 seconds? Then listen to MGC Pharmaceuticals co-founder and managing director, Roby Zomer discuss the company’s latest research announcement.

MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America.

The company recently announced the results of a pre-clinical study examining the effectiveness of cannabinoids in the treatment of high grade brain tumours.

Stockhead gave MGC Pharmaceuticals co-founder and managing director Roby Zomer 90 seconds to expand on the significance of the study and what sets it apart from similarly focused research.

Have a good idea for our next 90 Seconds With… segment? Email us at [email protected]